Rizavasertib

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C24H23N5O
Molecular Weight	397.4723
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC1=NNC2=CC=C(C=C12)C3=CC(OC[C@@H](N)CC4=CNC5=C4C=CC=C5)=CN=C3

InChI

InChIKey=YWTBGJGMTBHQTM-IBGZPJMESA-N

InChI=1S/C24H23N5O/c1-15-22-10-16(6-7-24(22)29-28-15)17-9-20(13-26-11-17)30-14-19(25)8-18-12-27-23-5-3-2-4-21(18)23/h2-7,9-13,19,27H,8,14,25H2,1H3,(H,28,29)/t19-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C24H23N5O
Molecular Weight	397.4723
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19465931 | https://www.ncbi.nlm.nih.gov/pubmed/18577685
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/19208828 | https://www.ncbi.nlm.nih.gov/pubmed/15956255

A-443654 is a potent and selective AKT inhibitor. A-443654 induces rapid Akt Ser-473 phosphorylation independent of mTORC1 inhibition. A-443654 interferes with mitotic progression by regulating aurora a kinase expression. A-443654 inhibits all three Akt isoforms in FL5.12 cells stably transfected with constitutively active myristoylated Akt1/2/3, and showed moderate selectivity when screened against related kinases in the AGC family, such as PKA and PKC20. A-443654 has being shown to extend survival in an intracranial glioma animal model. A-443654, either alone or in combination with existing drugs, may be a useful therapy for primary and drug-resistant T-ALL.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Serine/threonine-protein kinase AKT 31 Target ID: CHEMBL4282 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19465931 \| https://www.ncbi.nlm.nih.gov/pubmed/15956255	Inhibitor 8504		160.0 pM [Ki]

Conditions

Condition	Modality	Highest Phase	Product
Cancer 609 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20417028 https://www.ncbi.nlm.nih.gov/pubmed/19815839 https://www.ncbi.nlm.nih.gov/pubmed/17483438	Primary	Preclinical	Unknown Approved Use Unknown
Glioblastoma multiforme 30 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19208828	Primary	Preclinical	Unknown Approved Use Unknown
T-cell acute lymphoblastic leukemia 4 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18577685	Primary	Basic research	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
Rapamycin reverses pulmonary artery smooth muscle cell proliferation in pulmonary hypertension.	2013-05	23470622
Inhibitor hijacking of Akt activation.	2009-07	19465931
Inhibition of Akt inhibits growth of glioblastoma and glioblastoma stem-like cells.	2009-02	19208828

Patents

Sample Use Guides

In Vivo Use Guide

Mice: A-443654 was given s.c. in a vehicle of 0.2% HPMC.

Route of Administration: Other

In Vitro Use Guide

Treatment with A-443654 (0.5 uM), reduced FCS-stimulated growth of PA-SMCs (pulmonary artery smooth muscle cells) from MCT-PH rats to the level in control rats while inhibiting Akt, GSK3, and S6K activation.

Substance Class	Chemical Created by `admin` on `Wed Apr 02 17:51:13 GMT 2025` Edited by `admin` on `Wed Apr 02 17:51:13 GMT 2025`
Record UNII	Q4UG565ZYH
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

Rizavasertib

Official Name

English

A 443644

Preferred Name

English

rizavasertib [INN]

Common Name

English

1H-Indole-3-ethanamine, ?-[[[5-(3-methyl-1H-indazol-5-yl)-3-pyridinyl]oxy]methyl]-, (?S)-

Systematic Name

English

A-443644

Code

English

(2S)-1-(1H-Indol-3-yl)-3-[5-(3-methyl-2H-indazol-5-yl)pyridin-3-yl]oxypropan-2-amine

Systematic Name

English

A 443654

Code

English

A-443654

Code

English

Code System Code Type Description

EPA CompTox

DTXSID20436347